Canoderm is developed by Malmö University.

What development phase is Canoderm in?

Canoderm is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Canoderm

Malmö University · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Canoderm
Sponsor	Malmö University
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Treatment Effects of Two Pharmaceutical Skin Care Creams for Xerotic Feet Among Persons with Diabetes (PHASE4)
A Randomised Trial of a Moisturising Cream in Preventing Recurrence of Hand Eczema (PHASE4)
Skin Tolerance Study of Betamethasone Creams in Atopic Eczema and the Preventative Properties of a Moisturiser (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Canoderm CI brief — competitive landscape report
Canoderm updates RSS · CI watch RSS
Malmö University portfolio CI